Global HIV Therapeutics Market Size, Status and Forecast 2019-2025

Published On: Jun 2019

Format: PDF

Publisher: QY Research

Pages: 92

Report ID: 1562

The human immunodeficiency virus (HIV) refers to a type of retrovirus that causes acquired immunodeficiency syndrome (AIDS). HIV attacks some immune cells and causes weakness of immune system resulting in loss of ability to fight against the organism that causes disease.
HIV spreads through fluidic exchange with some infected person such as blood transfer or sharing needles with someone who is HIV infected. In addition, HIV can spread from infected mother to child during pregnancy. Some of the symptoms of HIV infection are slight fever, fatigue, swollen glands, headaches and muscle aches.
HIV infection has no cure but there are treatments which help to stabilize or reduce this infection so that it does not lead to AIDS. HIV therapeutics market is growing at a significant rate due to increase in the HIV infected cases and growing awareness about the same. HIV infection can be treated by various therapeutics such as nucleoside/ nucleotide reverse transcriptase inhibitor, integrase inhibitor, HIV-1 protease inhibitor, non-nucleoside reverse transcriptase inhibitor, pharmacokinetic enhancer and entry inhibitor.
In 2018, the global HIV Therapeutics market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global HIV Therapeutics status, future forecast, growth opportunity, key market and key players. The study objectives are to present the HIV Therapeutics development in United States, Europe and China.

The key players covered in this study
Boehringer Ingelheim International GmbH
Merck & Co.
ViiV Healthcare
AbbVie
F. Hoffmann-La Roche Ltd.
Teva Pharmaceutical Industries Ltd.
Bristol-Myers Squibb
Gilead Sciences
Johnson & Johnson
Cipla Limited

Market segment by Type, the product can be split into
Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Entry and Fusion Inhibitors
Protease Inhibitors (PIs)
Integrase Inhibitors
Coreceptor Antagonists

Market segment by Application, split into
Hospitals
Clinics
Labs

Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global HIV Therapeutics status, future forecast, growth opportunity, key market and key players.
To present the HIV Therapeutics development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of HIV Therapeutics are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.4.1 Global HIV Therapeutics Market Size Growth Rate by Type (2014-2025)
1.4.2 Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
1.4.3 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
1.4.4 Entry and Fusion Inhibitors
1.4.5 Protease Inhibitors (PIs)
1.4.6 Integrase Inhibitors
1.4.7 Coreceptor Antagonists
1.5 Market by Application
1.5.1 Global HIV Therapeutics Market Share by Application (2014-2025)
1.5.2 Hospitals
1.5.3 Clinics
1.5.4 Labs
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 HIV Therapeutics Market Size
2.2 HIV Therapeutics Growth Trends by Regions
2.2.1 HIV Therapeutics Market Size by Regions (2014-2025)
2.2.2 HIV Therapeutics Market Share by Regions (2014-2019)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Opportunities

3 Market Share by Key Players
3.1 HIV Therapeutics Market Size by Manufacturers
3.1.1 Global HIV Therapeutics Revenue by Manufacturers (2014-2019)
3.1.2 Global HIV Therapeutics Revenue Market Share by Manufacturers (2014-2019)
3.1.3 Global HIV Therapeutics Market Concentration Ratio (CR5 and HHI)
3.2 HIV Therapeutics Key Players Head office and Area Served
3.3 Key Players HIV Therapeutics Product/Solution/Service
3.4 Date of Enter into HIV Therapeutics Market
3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application
4.1 Global HIV Therapeutics Market Size by Type (2014-2019)
4.2 Global HIV Therapeutics Market Size by Application (2014-2019)

5 United States
5.1 United States HIV Therapeutics Market Size (2014-2019)
5.2 HIV Therapeutics Key Players in United States
5.3 United States HIV Therapeutics Market Size by Type
5.4 United States HIV Therapeutics Market Size by Application

6 Europe
6.1 Europe HIV Therapeutics Market Size (2014-2019)
6.2 HIV Therapeutics Key Players in Europe
6.3 Europe HIV Therapeutics Market Size by Type
6.4 Europe HIV Therapeutics Market Size by Application

7 China
7.1 China HIV Therapeutics Market Size (2014-2019)
7.2 HIV Therapeutics Key Players in China
7.3 China HIV Therapeutics Market Size by Type
7.4 China HIV Therapeutics Market Size by Application

8 Japan
8.1 Japan HIV Therapeutics Market Size (2014-2019)
8.2 HIV Therapeutics Key Players in Japan
8.3 Japan HIV Therapeutics Market Size by Type
8.4 Japan HIV Therapeutics Market Size by Application

9 Southeast Asia
9.1 Southeast Asia HIV Therapeutics Market Size (2014-2019)
9.2 HIV Therapeutics Key Players in Southeast Asia
9.3 Southeast Asia HIV Therapeutics Market Size by Type
9.4 Southeast Asia HIV Therapeutics Market Size by Application

10 India
10.1 India HIV Therapeutics Market Size (2014-2019)
10.2 HIV Therapeutics Key Players in India
10.3 India HIV Therapeutics Market Size by Type
10.4 India HIV Therapeutics Market Size by Application

11 Central & South America
11.1 Central & South America HIV Therapeutics Market Size (2014-2019)
11.2 HIV Therapeutics Key Players in Central & South America
11.3 Central & South America HIV Therapeutics Market Size by Type
11.4 Central & South America HIV Therapeutics Market Size by Application

12 International Players Profiles
12.1 Boehringer Ingelheim International GmbH
12.1.1 Boehringer Ingelheim International GmbH Company Details
12.1.2 Company Description and Business Overview
12.1.3 HIV Therapeutics Introduction
12.1.4 Boehringer Ingelheim International GmbH Revenue in HIV Therapeutics Business (2014-2019)
12.1.5 Boehringer Ingelheim International GmbH Recent Development
12.2 Merck & Co.
12.2.1 Merck & Co. Company Details
12.2.2 Company Description and Business Overview
12.2.3 HIV Therapeutics Introduction
12.2.4 Merck & Co. Revenue in HIV Therapeutics Business (2014-2019)
12.2.5 Merck & Co. Recent Development
12.3 ViiV Healthcare
12.3.1 ViiV Healthcare Company Details
12.3.2 Company Description and Business Overview
12.3.3 HIV Therapeutics Introduction
12.3.4 ViiV Healthcare Revenue in HIV Therapeutics Business (2014-2019)
12.3.5 ViiV Healthcare Recent Development
12.4 AbbVie
12.4.1 AbbVie Company Details
12.4.2 Company Description and Business Overview
12.4.3 HIV Therapeutics Introduction
12.4.4 AbbVie Revenue in HIV Therapeutics Business (2014-2019)
12.4.5 AbbVie Recent Development
12.5 F. Hoffmann-La Roche Ltd.
12.5.1 F. Hoffmann-La Roche Ltd. Company Details
12.5.2 Company Description and Business Overview
12.5.3 HIV Therapeutics Introduction
12.5.4 F. Hoffmann-La Roche Ltd. Revenue in HIV Therapeutics Business (2014-2019)
12.5.5 F. Hoffmann-La Roche Ltd. Recent Development
12.6 Teva Pharmaceutical Industries Ltd.
12.6.1 Teva Pharmaceutical Industries Ltd. Company Details
12.6.2 Company Description and Business Overview
12.6.3 HIV Therapeutics Introduction
12.6.4 Teva Pharmaceutical Industries Ltd. Revenue in HIV Therapeutics Business (2014-2019)
12.6.5 Teva Pharmaceutical Industries Ltd. Recent Development
12.7 Bristol-Myers Squibb
12.7.1 Bristol-Myers Squibb Company Details
12.7.2 Company Description and Business Overview
12.7.3 HIV Therapeutics Introduction
12.7.4 Bristol-Myers Squibb Revenue in HIV Therapeutics Business (2014-2019)
12.7.5 Bristol-Myers Squibb Recent Development
12.8 Gilead Sciences
12.8.1 Gilead Sciences Company Details
12.8.2 Company Description and Business Overview
12.8.3 HIV Therapeutics Introduction
12.8.4 Gilead Sciences Revenue in HIV Therapeutics Business (2014-2019)
12.8.5 Gilead Sciences Recent Development
12.9 Johnson & Johnson
12.9.1 Johnson & Johnson Company Details
12.9.2 Company Description and Business Overview
12.9.3 HIV Therapeutics Introduction
12.9.4 Johnson & Johnson Revenue in HIV Therapeutics Business (2014-2019)
12.9.5 Johnson & Johnson Recent Development
12.10 Cipla Limited
12.10.1 Cipla Limited Company Details
12.10.2 Company Description and Business Overview
12.10.3 HIV Therapeutics Introduction
12.10.4 Cipla Limited Revenue in HIV Therapeutics Business (2014-2019)
12.10.5 Cipla Limited Recent Development

13 Market Forecast 2019-2025
13.1 Market Size Forecast by Regions
13.2 United States
13.3 Europe
13.4 China
13.5 Japan
13.6 Southeast Asia
13.7 India
13.8 Central & South America
13.9 Market Size Forecast by Product (2019-2025)
13.10 Market Size Forecast by Application (2019-2025)

14 Analyst's Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
12.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Disclaimer
15.3 Author Details